Testing diabetes medicines on heart risk and heart failure
Part of Hormones & metabolism clinical trials.
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes
- You are considered at higher risk for heart and blood vessel problems
- You have heart failure with preserved ejection fraction (your heart’s pumping strength is preserved)
- You do NOT have type 1 diabetes
- You do NOT have kidney disease
- You do NOT have diabetic retinopathy (eye damage from diabetes)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This study compares different diabetes medicines to see which works best for people with type 2 diabetes who also have heart or blood vessel risks. It aims to find better treatment to protect your heart and kidneys.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
This study looks at whether two types of diabetes medications—SGLT2 inhibitors and GLP-1 receptor agonists—help protect the heart in people with type 2 diabetes. It involves a first group that reviews past medical records, and a second group that will be monitored for 6 months after starting an SGLT2 inhibitor to see how their heart function changes.
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.